While the German economy was characterized by having a merely inhospitable climate for biotechnology two decades ago (Dickman, 1996) , today the country has developed to one of Europe's leading biotechnology countries. As Müller (2002) outlines, the number of dedicated biotechnology firms has grown from 17 to 333 in the period between the early 1990s and 2001  thereby outpacing the number of biotech firms in the UK (271) and France (240). More recent data from the European cluster observatory (2016) show that the German biotechnology industry has manifested its leading role as national biotechnology player within Europe since then. The location quotient (LQ) in panel (a) of Figure A .1 compares the extent to which the national economies of Germany, the UK, France, and Switzerland have an above average concentration of biotechnology employment relative to the EU-27 average (indicated by LQ ≥ 1). As the figure shows, the industry concentration in Germany and the UK has been constantly above the EU-27 average for the sample period 1995-2010. In comparison, biotechnology-related employment concentration in Switzerland has rapidly grown in the second half of the last decade, while the LQ value for France has dropped considerably. Reasons for the striking decline in French biotechnology can be attributed to an increasing relocations of firms (particularly to Switzerland), a funding crisis with a drastic decline in equity investments and no active financial market as back-up (PharmaLetter, 2005a&b, BioSpace, 2009) combined with the worsening of the overall macroeconomic conditions in the course of the global financial and economic crisis (France Biotech, 2008) . The BioRegio contest, launched in 1995, can thereby be seen as a forerunner for this new type of (cluster) policy schemes, which Eickelpasch and Fritsch (2005) label as 'contests-for-cooperation'. The main idea of the BioRegio contest was to encourage regional cluster initiatives (so-called BioRegions) to form a common strategy and apply for subsidies to promote the biotechnology industry in the region (Dohse, 2000) . A crucial feature of the BioRegio contest was its design as a network and cluster policy since the contest promoted the spatial clustering of biotechnology actors in regional innovation systems (Dohse, 2000) . The underlying logic of this policy approach built on predictions from theoretical models in regional science and economic geography, which argued that spatial proximity and clustering of economic activities gives rise to increasing economies of scale through localization and urbanization advantages (McCann, 2013) . The funding concept of the BioRegio contest thereby aimed at developing a new holistic approach for research and technology policy and was planned to integrate biotechnological capacities and scientific, economic and administrative activities. Besides the purely monetary benefits for awarded BioRegions, participating in the contest was also considered attractive for non-winning participants, which could label themselves as part of the national network of BioRegions (organized as a registered association, for further information see Arbeitskreis BioRegionen https://www.biodeutschland.org/de/ak-bioregio.html) and potentially benefit from signaling effects due to the prestige of the contest. Moreover, the BioRegio contest was followed by the BioProfile contest starting in 1999 and its winners were mostly selected out of the original pool of BioRegions. As Figure A .4 visualizes for the "star" ranking from the European cluster observatory (based on German NUTS2 regions for the sample years 1998 and 2009), these funding programmes led to the prevalence of local clusters and fostered the development of strong regional nodes in the German biotechnology network, which can be linked to the associated BioRegions as shown in Figure A .4.
cluster observatory (2016) show that the German biotechnology industry has manifested its leading role as national biotechnology player within Europe since then. Figure A .1 plots different indicators characterizing the national innovation systems in biotechnology with regard to industry concentration (location quotient, see Isserman, 1977) , overall industry size as well as a composite "stars" indicator for the period 1995-2010. The European cluster observatory thereby defines the biotechnology industry according to the 4-digit level NACE Rev. 2 classification as 72.11 "Research and experimental development on biotechnology", which is in line with similar studies as in Laskawi (2015) .
The location quotient (LQ) in panel (a) of Figure A .1 compares the extent to which the national economies of Germany, the UK, France, and Switzerland have an above average concentration of biotechnology employment relative to the EU-27 average (indicated by LQ ≥ 1). As the figure shows, the industry concentration in Germany and the UK has been constantly above the EU-27 average for the sample period 1995-2010. In comparison, biotechnology-related employment concentration in Switzerland has rapidly grown in the second half of the last decade, while the LQ value for France has dropped considerably. Reasons for the striking decline in French biotechnology can be attributed to an increasing relocations of firms (particularly to Switzerland), a funding crisis with a drastic decline in equity investments and no active financial market as back-up (PharmaLetter, 2005a&b, BioSpace, 2009 ) combined with the worsening of the overall macroeconomic conditions in the course of the global financial and economic crisis (France Biotech, 2008) . Taking a closer look at the German development during this period, particularly massive deregulation, public funding, good provision of venture capital, a high rate of innovative start-ups and rapid localized knowledge transfers have been identified the major driving factors for the rapid progress of the industry in the 1990s (see, for instance, Dohse, 2000 , Müller, 2002 . The rise of the German biotechnology sector was thereby also supported by a global change in the worldwide technological regime of the industry, which evolved from an explorative state-of-art to a merely exploitative one. In the course of this structural shift, codified knowledge (rather than tacit) became increasingly important and facilitated the spreading of new ideas and research collaborations across longer distances (Ter Wal, 2014) . These developments paved the way for the emergence of multiple hot-spots of biotech activity in the geographical landscape of the industry's innovation system.
One specific indicator for the change in the technological regime in biotechnology is the growing importance of collaborative R&D activities (see, for instance, Roijakkers and Hagedoorn, 2006 , for the specific case of pharmaceutical biotechnology). Public support to collaborative R&D projects thereby also turned into the main focus of policy makers. As Figure The BioRegio contest, launched in 1995, can thereby be seen as a forerunner for this new type of (cluster) policy schemes, which Eickelpasch and Fritsch (2005) label as 'contests-for-cooperation'. The main idea of the BioRegio contest was to encourage regional cluster initiatives (so-called BioRegions) to form a common strategy and apply for subsidies to promote the biotechnology industry in the region (Dohse, 2000) . A crucial feature of the BioRegio contest was its design as a network and cluster policy since the contest promoted the spatial clustering of biotechnology actors in regional innovation systems (Dohse, 2000) . The underlying logic of this policy approach built on predictions from theoretical models in regional science and economic geography, which argued that spatial proximity and clustering of economic activities gives rise to increasing economies of scale through localization and urbanization advantages (McCann, 2013) . The funding concept of the BioRegio contest thereby aimed at developing a new holistic approach for research and technology policy and was planned to integrate biotechnological capacities and scientific, economic and administrative activities. 
